51³Ô¹ÏÍø

Director of neurological research Dr. Lennart Mucke in his office at the Gladstone Institutes in San Francisco, California, on Monday, November 18, 2013. Dr. Mucke has been studying a protein called beta amyloid, the primary target of Alzheimer's research

Director of neurological research Dr. Lennart Mucke in his office at the Gladstone Institutes in San Francisco, California, on Monday, November 18, 2013. Dr. Mucke has been studying a protein called beta amyloid, the primary target of Alzheimer's research. (Photo By Liz Hafalia/The San Francisco Chronicle via Getty Images)
Director of neurological research Dr. Lennart Mucke in his office at the Gladstone Institutes in San Francisco, California, on Monday, November 18, 2013. Dr. Mucke has been studying a protein called beta amyloid, the primary target of Alzheimer's research. (Photo By Liz Hafalia/The San Francisco Chronicle via Getty Images)
Director of neurological research Dr. Lennart Mucke in his office at the Gladstone Institutes in San Francisco, California, on Monday, November 18, 2013. Dr. Mucke has been studying a protein called beta amyloid, the primary target of Alzheimer's research
PURCHASE A LICENSE
How can I use this image?
€300.00
EUR
Getty ImagesDirector of neurological research Dr. Lennart Mucke in his office at..., News PhotoDirector of neurological research Dr. Lennart Mucke in his office at..., News PhotoDirector of neurological research Dr. Lennart Mucke in his office at... Get premium, high resolution news photos at Getty ImagesProduct #:1321624839
€475€115
Getty Images
In stock

DETAILS

Restrictions:
Contact your local office for all commercial or promotional uses.
Editorial #:
1321624839
Collection:
Hearst Newspapers
Date created:
November 18, 2013
Upload date:
License type:
Release info:
Not released.ÌýMore information
Source:
Hearst Newspapers
Object name:
health20alzheimers9
Max file size:
2592 x 3888 px (8.64 x 12.96 in) - 300 dpi - 6 MB